Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 15.22

(-8.86%)

Net Debt Summary of Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna's latest annual net debt in 2023 was 9.33 Million PLN , up 1450.17% from previous year.
Pure Biologics Spólka Akcyjna's latest quarterly net debt in 2024 Q2 was 13.12 Million PLN , up 66.92% from previous quarter.
Pure Biologics Spólka Akcyjna reported annual net debt of 602 Thousand PLN in 2022, up 119.64% from previous year.
Pure Biologics Spólka Akcyjna reported annual net debt of -3.06 Million PLN in 2021, up 22.42% from previous year.
Pure Biologics Spólka Akcyjna reported quarterly net debt of 7.96 Million PLN for 2024 Q1, down -14.64% from previous quarter.
Pure Biologics Spólka Akcyjna reported quarterly net debt of 9.33 Million PLN for 2023 Q4, down -73.13% from previous quarter.

Annual Net Debt Chart of Pure Biologics Spólka Akcyjna (2023 - 2016)

Historical Annual Net Debt of Pure Biologics Spólka Akcyjna (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	9.33 Million PLN	1450.17%
2022	602 Thousand PLN	119.64%
2021	-3.06 Million PLN	22.42%
2020	-3.95 Million PLN	53.78%
2019	-8.54 Million PLN	-8272.35%
2018	-102.1 Thousand PLN	8.88%
2017	-112.05 Thousand PLN	48.96%
2016	-219.51 Thousand PLN	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	13.12 Million PLN	66.92%
2024 Q1	7.96 Million PLN	-14.64%
2023 Q4	9.33 Million PLN	-73.13%
2023 Q1	21.48 Million PLN	3469.44%
2023 FY	9.33 Million PLN	1450.17%
2023 Q2	34.07 Million PLN	58.56%
2023 Q3	34.73 Million PLN	1.93%
2022 Q4	602 Thousand PLN	104.5%
2022 Q3	-13.36 Million PLN	44.94%
2022 FY	602 Thousand PLN	119.64%
2022 Q2	-24.27 Million PLN	17.77%
2022 Q1	-29.52 Million PLN	-863.16%
2021 Q2	-42.39 Million PLN	10.29%
2021 FY	-3.06 Million PLN	22.42%
2021 Q4	-3.06 Million PLN	91.41%
2021 Q3	-35.66 Million PLN	15.88%
2021 Q1	-47.25 Million PLN	-1096.08%
2020 Q4	-3.95 Million PLN	-111.4%
2020 FY	-3.95 Million PLN	53.78%
2020 Q3	-1.86 Million PLN	61.3%
2020 Q1	-6.79 Million PLN	35.28%
2020 Q2	-4.83 Million PLN	28.95%
2019 Q2	-4.82 Million PLN	-4136.68%
2019 FY	-8.54 Million PLN	-8272.35%
2019 Q4	-10.5 Million PLN	-705.25%
2019 Q3	-1.3 Million PLN	72.99%
2019 Q1	119.62 Thousand PLN	217.16%
2018 Q3	-379.22 Thousand PLN	0.0%
2018 FY	-102.1 Thousand PLN	8.88%
2018 Q1	267.04 Thousand PLN	338.33%
2018 Q4	-102.1 Thousand PLN	73.08%
2017 FY	-112.04 Thousand PLN	48.96%
2017 Q4	-112.05 Thousand PLN	0.0%
2016 FY	-219.51 Thousand PLN	0.0%

Peer Net Debt Comparison of Pure Biologics Spólka Akcyjna

Name	Net Debt	Net Debt Difference
Bioceltix S.A.	-9.13 Million PLN	202.154%
BIOTON S.A.	64.81 Million PLN	85.601%
Captor Therapeutics Spolka Akcyjna	-71.92 Million PLN	112.974%
Mabion S.A.	-11.98 Million PLN	177.838%
Molecure S.A.	-56.84 Million PLN	116.415%
NanoGroup S.A.	-537.61 Thousand PLN	1835.824%
Pharmena S.A.	-22.05 Million PLN	142.31%
Poltreg S.A.	-57.75 Million PLN	116.157%
Ryvu Therapeutics S.A.	-57.03 Million PLN	116.362%
Synthaverse S.A.	67.86 Million PLN	86.25%
Urteste S.A.	-512 Thousand PLN	1922.656%